Vivoryon Therapeutics NV
LSE:0R3M
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Vivoryon Therapeutics NV
LSE:0R3M
|
DE |
|
F
|
Farsoon Technologies Co Ltd
SSE:688433
|
CN |
|
SoftBank Corp
TSE:9434
|
JP |
|
B
|
Banco Itau Chile
SGO:ITAUCL
|
CL |
|
Telefonaktiebolaget LM Ericsson
STO:ERIC A
|
SE |
|
FILA Fabbrica Italiana Lapis ed Affini SpA
LSE:0QIQ
|
IT |
|
A
|
Ameriprise Financial Inc
XETRA:A4S
|
US |
|
S
|
Santam Ltd
JSE:SNT
|
ZA |
|
I
|
Insplorion AB
STO:INSP
|
SE |
|
LL Flooring Holdings Inc
NYSE:LL
|
US |
|
P
|
Publicis Groupe SA
DUS:PU4
|
FR |
|
C
|
Coca Cola HBC AG
OTC:CCHGY
|
CH |
|
L
|
Lowe's Companies Inc
XBER:LWE
|
US |
|
F
|
Ferrari NV
SWB:2FE
|
IT |
|
Grupo Aeroportuario del Pacifico SAB de CV
F:G9N1
|
MX |
|
E
|
EDP Renovaveis SA
ELI:EDPR
|
ES |
Bankruptcy Probability
Vivoryon Therapeutics NV's probability of bankruptcy is Hidden . The solvency score is Hidden .
We take all the information about a company's solvency, such as how easily it can pay interest on outstanding debt, how much cash it has, the amount of debt, and more, and use it to estimate the probability of bankruptcy.
Solvency Ratios
Solvency Ratios Comparison
Vivoryon Therapeutics NV Competitors
| Country | Company | Market Cap | D/E | D/A |
Interest Coverage |
Altman Z-Score |
Quick Ratio |
Current Ratio |
Cash Ratio |
||
|---|---|---|---|---|---|---|---|---|---|---|---|
| DE |
|
Vivoryon Therapeutics NV
AEX:VVY
|
36.9m EUR |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
381.3B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
183.2B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
166.9B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
110.5B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
67.5B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
43.4B EUR |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
39.7B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Vivoryon Therapeutics NV's probability of bankruptcy is Hidden .
The probability of bankruptcy is estimated using credit risk models that assess financial health, debt levels, interest coverage, and other solvency indicators.
As of the latest report, Vivoryon Therapeutics NV has total debt of 11k EUR. This includes both short-term (0 EUR) and long-term (11k EUR) debt.
You can find a full breakdown on its Balance Sheet.
